News Bell: Carnival Corporation (CCL), Boston Scientific Corporation (BSX)

9

Carnival Corporation (CCL)

Carnival Corporation & plc is the largest cruise company in the world, with a portfolio of 10 cruise brands in North America, Europe, Australia and Asia, comprised of Carnival Cruise Line, Holland America Line, Princess Cruises, Seabourn, AIDA Cruises, Costa Cruises, Cunard, P&O Cruises (Australia), P&O Cruises (UK) and Fathom.

Carnival Corporation (CCL)‘s Financial Overview

Carnival Corporation (CCL) declined -1.66% yesterday to close its trading session at $64.64. The company has 1 year Price Target of $77.6. The stock touched its 52-Week High on Obsolete and 52-Week Low on Obsolete. The stock traded with the volume of 5.39 Million shares yesterday. The firm shows the market capitalization of $47.55 Billion.

The firm is trading with SMA20 of -2.77 Percent, SMA50 of SMA50 Percent and SMA200 of -3.42 percent. Carnival Corporation has P/S value of 2.72 while its P/B value stands at 1.9. Similarly, the company has Return on Assets of 6.5 percent, Return on Equity of 11.1 percent and Return on Investment of 8.2 Percent. The company shows Gross Margin and Operating Margin of 40 percent and 16.3 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 23 analysts offering 12-month price forecasts for Carnival Corp have a median target of 78.00, with a high estimate of 84.00 and a low estimate of 64.00. The median estimate represents a +20.67% increase from the last price of 64.64.

Boston Scientific Corporation (BSX)

Boston Scientific Corporation transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader they advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

Boston Scientific Corporation (BSX)‘s Financial Outlook

The 25 analysts offering 12-month price forecasts for Boston Scientific Corp have a median target of 31.00, with a high estimate of 35.00 and a low estimate of 26.00. The median estimate represents a +16.19% increase from the last price of 26.68.

According to Zacks Investment Research, Boston Scientific Corporation has a Consensus Recommendation of 1.45. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock declined-1.29% and closed its last trading session at $26.68. The company has the market capitalization of $37.58 Billion. The firm touched its 52-Week high on Obsolete and 52-Week low on Obsolete. The company has volume of 5.37 Million shares. The company has a total of 1.41 Billion shares outstanding.

The company has YTD performance of 7.62 percent. Beta for Boston Scientific Corporation stands at 0.83 while its ATR (average true range) is 0.6. The company has Weekly Volatility of 2.80%% and Monthly Volatility of 2.11%.

Boston Scientific Corporation has distance from 20-day Simple Moving Average (SMA20) of -3.08%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of -2.98%.

The Company currently has ROA (Return on Assets) of 0.6 percent, Return on Equity (ROE) of 1.4 Percent and Return on Investment (ROI) of 10.4% with Gross margin of 71.8 percent and Operating & Profit margin of 14.2% and 1.1% respectively.

 

SHARE